Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 3 , Pages 301-307 , March 2010

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)

  • Douglas J. Biedenbach

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-665-3370; fax: +1-319-665-3371.
    • ,
  • Paul R. Rhomberg

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • ,
  • Rodrigo E. Mendes

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • Tufts University School of Medicine, Boston, MA 02111, USA

Received 19 September 2009 ,Accepted 21 October 2009.

References 

  1. Anderson JD. Fusidic acid: new opportunities with an old antibiotic. Can. Med. Assoc. J. 1980;122:765–769
  2. Clinical and Laboratory Standards Institute (CLSI) . Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard—seventh edition, M11-A7. Wayne, PA: CLSI; 2008;
  3. Clinical and Laboratory Standards Institute (CLSI) . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—eighth edition, M07-A8. Wayne, PA: CLSI; 2009;
  4. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19). Wayne, PA: CLSI; 2009;
  5. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int. J. Antimicrob. Agents. 1999;12(Suppl. 2):S45–S58
  6. Corey GR. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin. Infect. Dis. 2009;48(Suppl. 4):S254–S259
  7. Cornaglia G, Rossolini GM. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 2009;15:218–223
  8. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence. Clin Infect Dis. 2007;44:1543–1548
  9. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2009;199:605–609
  10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 2006;166:2138–2144
  11. Howden BP, Grayson ML. Dumb and dumber—the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 2006;42:394–400
  12. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004;38:521–528
  13. Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg. Infect. Dis. 2007;13:1024–1030
  14. Lannergard J, Norstrom T, Hughes D. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 2009;53:2059–2065
  15. Larsen AR, Skov RL, Jarlier V, Henriksen AS. Epidemiological differences between the UK and Ireland versus France in Staphylococcus aureus isolates resistant to fusidic acid from community-acquired skin and soft tissue infections. J. Antimicrob. Chemother. 2008;61:589–594
  16. Laurent F, Tristan A, Croze M, Bes M, Meugnier H, Lina G, et al. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J. Antimicrob. Chemother. 2009;63:420–421
  17. Lewis JS, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 2005;49:1664–1665
  18. Lode HM. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 2009;15:212–217
  19. Mason BW, Howard AJ, Magee JT. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J. Antimicrob. Chemother. 2003;51:1033–1036
  20. McLaws F, Chopra I, O'Neill AJ. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis. J. Antimicrob. Chemother. 2008;61:1040–1043
  21. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 2008;52:2244–2246
  22. O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J. Clin. Microbiol. 2007;45:1505–1510
  23. Rennie RP. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J. Cutan. Med. Surg. 2006;10:277–280
  24. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 2006;44:655–656
  25. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008;46(Suppl. 5):S368–S377
  26. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 2007;44:1208–1215
  27. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 2007;64:1506–1514
  28. Tveten Y, Jenkins A, Kristiansen BE. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. J. Antimicrob. Chemother. 2002;50:873–876

PII: S0732-8893(09)00424-6

doi: 10.1016/j.diagmicrobio.2009.10.014

Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 3 , Pages 301-307 , March 2010

Article Tools

* Image Usage & Resolution